Abstract:Purpose: High grade pleomorphic xanthoastrocytomas (HGPXAs) are very rare and their management and prognostic outcomes remain unclear. To better understand the disease, we aimed to evaluate the risk factors for progression-free survival (PFS) and overall survival (OS), and propose a treatment protocol based on cases from our institute and cases from the literature. Methods: The authors reviewed the clinical data of 26 patients with HGPXAs who underwent surgical treatment in Department of Neurosurgery of Beijing Tiantan Hospital between August 2014 and September 2021. We also searched the PubMed database using the keywords "anaplastic" combined with "pleomorphic xanthoastrocytoma(s)" between January 1997 and October 2022. Risk factors for PFS and OS were evaluated in the pooled cases. Results: The authors' cohort included 11 males and 15 females with a mean age of 36.7 ± 20.3 years (range: 5.5-71 years). Gross-total resection (GTR) and non-GTR were achieved in 17 (65.4%) and 9 (34.6%) patients, respectively. Radiotherapy and chemotherapy were administered to 22 and 20 patients, respectively. After a mean follow-up of 20.5 ± 21.2 months (range: 0.5-78.1 months), 7 patients suffered tumor recurrence and 6 patients died with a mean OS time of 19.4 ± 10.8 months (range: 8-36 months). In the literature between January 1997 and October 2022, 56 cases of HGPXAs were identified in 29 males and 27 females with a mean age of 29.6 ± 19.6 years (range; 4-74 years). Among them, 24 (44.4%) patients achieved GTR. Radiotherapy and chemotherapy was administered to 31 (62%) patients and 23 (46%) patients, respectively. After a median follow-up of 31.4 ± 35.3 months (range: 0.75-144 months), the mortality and recurrence rates were 32.5% (13/40) and 70% (28/40), respectively. Multivariate Cox regression model demonstrated that non-GTR (HR 0.380, 95% CI 0.174-0.831, p=0.015), age≥30 (HR 2.620, 95% CI 1.183-5.804, p=0.018), no RT (HR 0.334,95% CI 0.150-0.744, p=0.007) and no CT (HR 0.422, 95% CI 0.184-0.967, p=0.042) were negative prognostic factors for PFS. Non-GTR (HR 0.126, 95% CI 0.037-0.422, p=0.001), secondary HGPXAs (HR 7.567, 95% CI 2.221-25.781, p=0.001), age≥30 (HR 3.568, 95% CI 1.190-10.694, p=0.023) and no RT (HR 0.223,95% CI 0.073-0.681, p=0.008) were risk factors for OS. Conclusion:: High grade pleomorphic xanthoastrocytomas are very rare brain tumors. Children and younger adults have better clinical outcome than elderly patients. Secondary HGPXAs had worse OS than primary HGPXAs. Complete surgical excision plus RT and CT is recommended for this entity. The frequency of BRAF mutations in HGPXAs is 47.5% (19/40) in this study, however, we do not find the connections between BRAF mutations and clinical outcomes. Future studies with larger cohorts are necessary to verify our findings.

BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study

Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma

Clinicopathological, Morphological and Molecular study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma

Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, and Epithelioid Glioblastoma: Case Series with Clinical Characteristics, Molecular Features and Progression Relationship

Molecular Features of Pleomorphic Xanthoastrocytoma.

Exploring prognostic factors and treatment strategies for long-term survival in pleomorphic xanthoastrocytoma patients

Molecular Characterization of Clinically Defined Aggressive Variant Prostate Cancer (avpca) in Prospectively Collected Tissues and Corresponding Patient Derived Xenografts (PDX).

Clinical features and surgical outcomes of high grade pleomorphic xanthoastrocytomas: a single-center experience with a systematic review

Biom-42. Response To Dabrafenib/Trametinib In A Patient With Who-Cns Grade 3 Braf V600E-Mutated Pleomorphic Xanthoastrocytoma

Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma

Clinical Manifestations And Outcomes Of Typical Versus Atypical Pleomorphic Xanthoastrocytoma: A Single-Institution Experience

Analysis of Comparative Genomic Hybridization in Pleomorphic Xanthoastrocytoma

Anaplastic Pleomorphic Xanthoastrocytoma with Disseminated Growth Pattern at the Time of Diagnosis As Well As after Treatment: Case Report and Review of Literature

Infratentorial Pleomorphic Xanthoastrocytoma: Report Of Two Cases And Review Of Literature

Pleomorphic Xanthoastrocytoma: Multi-Institutional Evaluation of Stereotactic Radiosurgery

Surg-02. Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal Dissemination Presenting With Cranial Neuropathy In An Adult Patient: Illustrative Case And Review Of The Literature

Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma

An integrative analysis of treatment, outcomes and prognostic factors for primary spinal anaplastic ependymomas.

BRAF Non-V600e More Frequently Co-Occurs with IDH1/2 Mutations in Adult Patients with Gliomas Than in Patients Harboring BRAF V600E but Without a Survival Advantage

PATH-34. H3F3A AND TERT PROMOTER MUTATIONS ARE POOR PROGNOSTICATORS IN PEDIATRIC LOW-GRADE GLIOMAS

Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging